What is Brendan Bioscience?
Brendan Bioscience, LLC operates as a specialized manufacturer of Class 1 Analyte Specific Reagents, maintaining an ISO 13485 certified GMP facility in Hopedale, Massachusetts. Since its inception in 2004 by Dr. Brent Dorval, the organization has carved out a critical niche in the development of patented reagent components essential for clinical researchers and CLIA-certified laboratories. The company's primary focus remains on advancing immunoassay development, particularly for applications in Delayed Food Sensitivity research and testing. By adhering to stringent FDA regulations and international quality standards, Brendan Bioscience provides the foundational tools necessary for high-complexity diagnostic environments, ensuring precision and reliability in clinical outcomes.
How much funding has Brendan Bioscience raised?
Brendan Bioscience has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
Key Investors in Brendan Bioscience
PPP
Public-Private Partnership
What's next for Brendan Bioscience?
With the recent influx of capital, Brendan Bioscience is positioned to scale its manufacturing capabilities and deepen its commitment to immunoassay innovation. The strategic deployment of these funds will likely focus on enhancing production efficiency within its GMP-certified facility to meet the growing demand for specialized diagnostic reagents. As the company navigates the complexities of the late-stage growth phase, it remains focused on maintaining its regulatory excellence while potentially expanding its product portfolio to address emerging needs in clinical research. This financial backing provides the necessary runway to accelerate research initiatives and strengthen the company's market presence as a trusted partner for complex laboratory testing.
See full Brendan Bioscience company page
